Carcinoembryonic antigen (CEA) is recommended for use in surveillance of recurrence by 13 (72.2%) colorectal cancer guidelines, all prostate cancer guidelines (n=8) recommend the use of PSA and nine guidelines (90%) for bladder cancer recommend the use of urine cytology. This evidence concerns the gene CEACAM5 and prostate cancer.